Suchergebnisse - "Varghese, Anna M."

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer von Yaeger, Rona, Chatila, Walid K, Lipsyc, Marla D, Hechtman, Jaclyn F, Cercek, Andrea, Sanchez-Vega, Francisco, Jayakumaran, Gowtham, Middha, Sumit, Zehir, Ahmet, Donoghue, Mark T A, You, Daoqi, Viale, Agnes, Kemeny, Nancy, Segal, Neil H, Stadler, Zsofia K, Varghese, Anna M, Kundra, Ritika, Gao, Jianjiong, Syed, Aijazuddin, Hyman, David M, Vakiani, Efsevia, Rosen, Neal, Taylor, Barry S, Ladanyi, Marc, Berger, Michael F, Solit, David B, Shia, Jinru, Saltz, Leonard, Schultz, Nikolaus

“… Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis of this variability remains poorly understood. We performed …”
Weitere Angaben

Ordered and deterministic cancer genome evolution after p53 loss von Baslan, Timour, Morris, John P., Zhao, Zhen, Reyes, Jose, Ho, Yu-Jui, Tsanov, Kaloyan M., Bermeo, Jonathan, Tian, Sha, Zhang, Sean, Askan, Gokce, Yavas, Aslihan, Lecomte, Nicolas, Erakky, Amanda, Varghese, Anna M., Zhang, Amy, Kendall, Jude, Ghiban, Elena, Chorbadjiev, Lubomir, Wu, Jie, Dimitrova, Nevenka, Chadalavada, Kalyani, Nanjangud, Gouri J., Bandlamudi, Chaitanya, Gong, Yixiao, Donoghue, Mark T. A., Socci, Nicholas D., Krasnitz, Alex, Notta, Faiyaz, Leach, Steve D., Iacobuzio-Donahue, Christine A., Lowe, Scott W.

“… Although p53 inactivation promotes genomic instability 1 and presents a route to malignancy for more than half of all human cancers 2 , 3 , the patterns …”
Volltext

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations von Hu, Zishuo I, Shia, Jinru, Stadler, Zsofia K, Varghese, Anna M, Capanu, Marinela, Salo-Mullen, Erin, Lowery, Maeve A, Diaz, Jr, Luis A, Mandelker, Diana, Yu, Kenneth H, Zervoudakis, Alice, Kelsen, David P, Iacobuzio-Donahue, Christine A, Klimstra, David S, Saltz, Leonard B, Sahin, Ibrahim H, O'Reilly, Eileen M

“… Immune checkpoint inhibition has been shown to generate profound and durable responses in mismatch repair deficient (MMR-D) solid tumors and has elicited …”
Weitere Angaben

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience von Glassman, Danielle C., Palmaira, Randze L., Covington, Christina M., Desai, Avni M., Ku, Geoffrey Y., Li, Jia, Harding, James J., Varghese, Anna M., O’Reilly, Eileen M., Yu, Kenneth H.

“… Background Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of …”
Volltext

Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review von Singh, Ritu R., Goldberg, Johanna, Varghese, Anna M., Yu, Kenneth H., Park, Wungki, O'Reilly, Eileen M.

“… •Genomic alterations in PDAC represent potential targeting opportunities to individualize therapy.•Attempts to target key somatic driver mutations in PDAC have …”
Volltext

Current management and future directions in metastatic pancreatic adenocarcinoma von Varghese, Anna M., Lowery, Maeve A., Yu, Kenneth H., O'Reilly, Eileen M.

“… Of the anticipated 50,000 individuals expected to be diagnosed with pancreatic cancer in 2016, the majority will have metastatic disease. Given the noncurative …”
Volltext

Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system von Tringale, Kathryn R., Tyagi, Neelam, Marsha Reyngold, Romesser, Paul B., Wu, Abraham, O'Reilly, Eileen M., Varghese, Anna M., Godoy Scripes, Paola, Khalil, Danny N., Park, Wungki, Yu, Kenneth, Crane, Christopher H.

“… •Ablative radiation therapy (A-RT) is effective for locally advanced pancreas cancer.•30 patients received A-RT using diagnostic quality MR-adaptive treatment …”
Volltext

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer von Rojas, Luis A., Sethna, Zachary, Soares, Kevin C., Olcese, Cristina, Pang, Nan, Patterson, Erin, Lihm, Jayon, Ceglia, Nicholas, Guasp, Pablo, Chu, Alexander, Yu, Rebecca, Chandra, Adrienne Kaya, Waters, Theresa, Ruan, Jennifer, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Payne, George, Derhovanessian, Evelyna, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Dobrin, Anton, Sadelain, Michel, Łuksza, Marta, Cohen, Noah, Tang, Laura, Basturk, Olca, Gönen, Mithat, Katz, Seth, Do, Richard Kinh, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Mellman, Ira, Merghoub, Taha, Wolchok, Jedd D., Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., Balachandran, Vinod P.

“… Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2 , 3 …”
Volltext

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer von Latham, Alicia, Srinivasan, Preethi, Kemel, Yelena, Shia, Jinru, Bandlamudi, Chaitanya, Mandelker, Diana, Middha, Sumit, Hechtman, Jaclyn, Zehir, Ahmet, Dubard-Gault, Marianne, Tran, Christina, Stewart, Carolyn, Sheehan, Margaret, Penson, Alexander, DeLair, Deborah, Yaeger, Rona, Vijai, Joseph, Mukherjee, Semanti, Galle, Jesse, Dickson, Mark A, Janjigian, Yelena, O'Reilly, Eileen M, Segal, Neil, Saltz, Leonard B, Reidy-Lagunes, Diane, Varghese, Anna M, Bajorin, Dean, Carlo, Maria I, Cadoo, Karen, Walsh, Michael F, Weiser, Martin, Aguilar, Julio Garcia, Klimstra, David S, Diaz, Jr, Luis A, Baselga, Jose, Zhang, Liying, Ladanyi, Marc, Hyman, David M, Solit, David B, Robson, Mark E, Taylor, Barry S, Offit, Kenneth, Berger, Michael F, Stadler, Zsofia K

“… Microsatellite instability (MSI) and/or mismatch repair deficiency (MMR-D) testing has traditionally been performed in patients with colorectal (CRC) and …”
Weitere Angaben

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer von Sethna, Zachary, Guasp, Pablo, Reiche, Charlotte, Milighetti, Martina, Ceglia, Nicholas, Patterson, Erin, Lihm, Jayon, Payne, George, Lyudovyk, Olga, Rojas, Luis A., Pang, Nan, Ohmoto, Akihiro, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Bruno, Emmanuel M., Zhang, Siqi Linsey, Cheng, Charlotte, Elhanati, Yuval, Derhovanessian, Evelyna, Manning, Luisa, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Merghoub, Taha, Wolchok, Jedd D., Basturk, Olca, Gönen, Mithat, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Soares, Kevin C., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., Mellman, Ira, Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Balachandran, Vinod P.

“… A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA–lipoplex …”
Volltext

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer von Gainor, Justin F, Varghese, Anna M, Ou, Sai-Hong Ignatius, Kabraji, Sheheryar, Awad, Mark M, Katayama, Ryohei, Pawlak, Amanda, Mino-Kenudson, Mari, Yeap, Beow Y, Riely, Gregory J, Iafrate, A John, Arcila, Maria E, Ladanyi, Marc, Engelman, Jeffrey A, Dias-Santagata, Dora, Shaw, Alice T

“… Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct molecular subset of non-small cell lung cancer (NSCLC). Recently, several case reports …”
Weitere Angaben

CAR T‐cell therapy for pancreatic cancer von DeSelm, Carl J., Tano, Zachary E., Varghese, Anna M., Adusumilli, Prasad S.

“… Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results …”
Volltext

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study von Sullivan, Ryan J, Infante, Jeffrey R, Janku, Filip, Wong, Deborah Jean Lee, Sosman, Jeffrey A, Keedy, Vicki, Patel, Manish R, Shapiro, Geoffrey I, Mier, James W, Tolcher, Anthony W, Wang-Gillam, Andrea, Sznol, Mario, Flaherty, Keith, Buchbinder, Elizabeth, Carvajal, Richard D, Varghese, Anna M, Lacouture, Mario E, Ribas, Antoni, Patel, Sapna P, DeCrescenzo, Gary A, Emery, Caroline M, Groover, Anna L, Saha, Saurabh, Varterasian, Mary, Welsch, Dean J, Hyman, David M, Li, Bob T

“… Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial …”
Weitere Angaben

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms von Lowery, Maeve A, Wong, Winston, Jordan, Emmet J, Lee, Jonathan W, Kemel, Yelena, Vijai, Joseph, Mandelker, Diana, Zehir, Ahmet, Capanu, Marinela, Salo-Mullen, Erin, Arnold, Angela G, Yu, Kenneth H, Varghese, Anna M, Kelsen, David P, Brenner, Robin, Kaufmann, Erica, Ravichandran, Vignesh, Mukherjee, Semanti, Berger, Michael F, Hyman, David M, Klimstra, David S, Abou-Alfa, Ghassan K, Tjan, Catherine, Covington, Christina, Maynard, Hannah, Allen, Peter J, Askan, Gokce, Leach, Steven D, Iacobuzio-Donahue, Christine A, Robson, Mark E, Offit, Kenneth, Stadler, Zsofia K, O'Reilly, Eileen M

“… Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive …”
Weitere Angaben

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer von Bendell, Johanna C, Varghese, Anna M, Hyman, David M, Bauer, Todd M, Pant, Shubham, Callies, Sophie, Lin, Ji, Martinez, Ricardo, Wickremsinhe, Enaksha, Fink, Aaron, Wacheck, Volker, Moore, Kathleen N

“… The PI3K/mTOR pathway is frequently aberrated in cancer. LY3023414 is a potent and selective ATP-competitive inhibitor of class I PI3K isoforms, mTOR, and …”
Weitere Angaben

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels von Stadler, Zsofia K, Battaglin, Francesca, Middha, Sumit, Hechtman, Jaclyn F, Tran, Christina, Cercek, Andrea, Yaeger, Rona, Segal, Neil H, Varghese, Anna M, Reidy-Lagunes, Diane L, Kemeny, Nancy E, Salo-Mullen, Erin E, Ashraf, Asad, Weiser, Martin R, Garcia-Aguilar, Julio, Robson, Mark E, Offit, Kenneth, Arcila, Maria E, Berger, Michael F, Shia, Jinru, Solit, David B, Saltz, Leonard B

“… Tumor screening for Lynch syndrome is recommended in all or most patients with colorectal cancer (CRC). In metastatic CRC, sequencing of RAS/BRAF is necessary …”
Weitere Angaben

Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer von Reyngold, Marsha, O'Reilly, Eileen M, Varghese, Anna M, Fiasconaro, Megan, Zinovoy, Melissa, Romesser, Paul B, Wu, Abraham, Hajj, Carla, Cuaron, John J, Tuli, Richard, Hilal, Lara, Khalil, Danny, Park, Wungki, Yorke, Ellen D, Zhang, Zhigang, Yu, Kenneth H, Crane, Christopher H

“… Surgical resection has been considered the only curative option for patients with pancreatic cancer. Nonoperative local treatment options that can provide a …”
Weitere Angaben

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival von Varghese, Anna M, Perry, Maria A, Chou, Joanne F, Nandakumar, Subhiksha, Muldoon, Daniel, Erakky, Amanda, Zucker, Amanda, Fong, Christopher, Mehine, Miika, Nguyen, Bastien, Basturk, Olca, Balogun, Fiyinfolu, Kelsen, David P, Brannon, A Rose, Mandelker, Diana, Vakiani, Efsevia, Park, Wungki, Yu, Kenneth H, Stadler, Zsofia K, Schattner, Mark A, Jarnagin, William R, Wei, Alice C, Chakravarty, Debyani, Capanu, Marinela, Schultz, Nikolaus, Berger, Michael F, Iacobuzio-Donahue, Christine A, Bandlamudi, Chaitanya, O'Reilly, Eileen M

“… Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and …”
Weitere Angaben

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype von Lowery, Maeve A, Jordan, Emmet J, Basturk, Olca, Ptashkin, Ryan N, Zehir, Ahmet, Berger, Michael F, Leach, Tanisha, Herbst, Brian, Askan, Gokce, Maynard, Hannah, Glassman, Danielle, Covington, Christina, Schultz, Nikolaus, Abou-Alfa, Ghassan K, Harding, James J, Klimstra, David S, Hechtman, Jaclyn F, Hyman, David M, Allen, Peter J, Jarnagin, William R, Balachandran, Vinod P, Varghese, Anna M, Schattner, Mark A, Yu, Kenneth H, Saltz, Leonard B, Solit, David B, Iacobuzio-Donahue, Christine A, Leach, Steven D, O'Reilly, Eileen M

“… Molecular profiling in cancer has identified potential actionable drug targets that have prompted attempts to discover clinically validated biomarkers to guide …”
Weitere Angaben

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice von Park, Wungki, O'Connor, Catherine A, Bandlamudi, Chaitanya, Forman, Daniella, Chou, Joanne F, Umeda, Shigeaki, Reyngold, Marsha, Varghese, Anna M, Keane, Fergus, Balogun, Fiyinfolu, Yu, Kenneth H, Kelsen, David P, Crane, Christopher, Capanu, Marinela, Iacobuzio-Donahue, Christine, O'Reilly, Eileen M

“… Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for …”
Weitere Angaben